791111-79-0

Upstream product

• 1149-26-4 (S)-N-(benzyloxycarbonyl)valine 
• 68858-20-8 Fmoc-Val-OH 
• 71989-31-6 Fmoc-Pro-OH 
• 791111-78-9 Z-Val-Pro-Val-Pro-OtBu 

Downstream Products

• 791111-72-3 Z-Val-Pro-Val-Pro-Ara-C 
• 1203578-20-4 4-N-[Nα-(benzyloxycarbonyl)valylprolylvalylprolyl]-3',5'-bis-O-(tert-butyldimethylsilyl)-1-β-D-arabinofuranosyladenine 
• 1203578-16-8 [1-[2',5'-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]-4-N-[Nα-(benzyloxycarbonyl)-valyl-prolyl-valyl-prolyl]cytosine]-3'-spiro-5''-[4''-amino-1'',2''-oxathiole-2'',2''-dioxide] 

Relevant academic research and scientific papers

Application of the dipeptidyl peptidase IV (DPPIV/CD26) based prodrug approach to different amine-containing drugs

Here we explore the applicability of the dipeptidyl peptidase IV (DPPIV/CD26) based prodrug approach to a variety of amine-containing drugs. Efficient procedures have been developed for the synthesis of dipeptide and tetrapeptide amide prodrugs including

PRODRUGS CLEAVABLE BY CD26

The present invention provides a new prodrug technology and new prodrugs in order to increase the solubility, to modulate plasma protein binding or to enhance the biovailability of a drug. In the present invention the prodrugs are conjugates of a therapeutic compound and a peptide (eg tetrapeptide or hexapeptide) wherein the conjugate is cleavable by dipeptidyl-peptidases, more preferably by CD26, also known as DPPIV (dipeptidyl aminodipeptidase IV). The present invention furthermore provides a method of producing said prodrugs, to enhance brain and lymphatic delivery of drugs and/or to extend drug half-lives in plasma.